A Clinical Trial of Switching to Vilazodone for Antidepressant-Associated Sexual Dysfunction
Brief description of study
a research study for a new antidepressant called vilazodone, which is suspected to have fewer negative effects on sexual functioning than other medications that are used to treat depression. Vilazodone is commercially available under the name Viibryd ™. Currently, vilazodone has been approved by the United States Food and Drug Administration (FDA) as a treatment for major depressive disorder. This study will measure any improvement in the sexual side effects that may occur in patients who are switched to vilazodone or sertraline.
The purpose of this study is to help answer the following questions:
• Do patients with sexual dysfunction from taking an antidepressant who are switched to vilazodone have greater improvement in sexual functioning than those patients who are switched to sertraline?
• Can vilazodone help patients with major depressive disorder as well as the antidepressant that the patient was taking to treat the disorder?
Detailed description of study
Your involvement in the study will last about 13-17 weeks. This study consists of 4 different study periods, a Screening phase (which may last from 3 – 30 days), a 2-week Cross Taper phase, an 8-week Treatment phase, and an optional 2-week Down Taper phase.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Depression, Depression, medication, drug therapy
-
Age: Between 18 Years - 65 Years
-
Gender: All
Updated on
16 Aug 2016.
Study ID: 816979
